Viking Therapeutics

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapies for patients suffering from metabolic and endocrine disorders. The firm's clinical program, VK5211, treats patients recovering from non-elective hip fracture surgery. It also specializes in the development of VK2809 and VK0214. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Viking Therapeutics reports solid financials and advances in clinical programs

Viking Therapeutics showcased a strong financial position and progress in clinical programs for various disorders
Challenges include observing full efficacy in short studies and balancing efficacy with safety in dose decisions
Opportunities lie in achieving target efficacy ranges, optimizing dosing based on data, and releasing comprehensive study results

Viking Therapeutics reports Q1 progress and financial stability post-offering

Viking Therapeutics showcased progress in clinical programs and financial stability post-public offering.
Analyst inquiries focused on tolerability, dosing, and expectations for top-line results of key compounds.
Challenges include managing expenses, PK/PD profile comparisons, and uncertainties in enrollment for upcoming studies.
Opportunities lie in pipeline expansions, confidence in oral formulation data, and potential combination studies for future growth.

Viking Therapeutics excels in clinical trials and financial stability

Viking Therapeutics delivered strong clinical and financial performance in Q2 2023, positioning itself well in the NASH and obesity markets.
The company's methodical approach to clinical trials and focus on internal development underscore a strategic and disciplined growth strategy.
While facing financial challenges and operational complexities, Viking has opportunities to leverage positive trial results and cash reserves for future growth.
Overall, Viking's Q2 performance reflects a balanced pursuit of innovation, financial prudence, and strategic advancement in its pipeline.

Viking Therapeutics reports robust Q3 performance and eyes combination therapies

Viking Therapeutics showcased strong clinical data and financial stability in Q3 2023, with key trials progressing as planned.
While facing challenges like limited MRI data and formulation complexities, the company's commitment to innovation and scalability remains evident.
Opportunities lie in exploring combination therapies, addressing patient preferences, and leveraging market trends for future growth.
Overall, Viking's performance, strengths, and strategic outlook position them well for continued success in the biopharmaceutical sector.

Viking Therapeutics excels in clinical trials and financial growth

Viking Therapeutics showcased positive trial results, financial strength, and a proactive approach to advancing their pipeline. While facing challenges in managing expenses and navigating regulatory requirements, the company remains optimistic about the potential of their clinical programs. Opportunities for growth exist through successful trial outcomes, strategic partnerships, and regulatory engagements.

Viking Therapeutics reports strong Q1 results and plans pipeline expansion

Viking Therapeutics showcased positive clinical outcomes for VK2735 and VK2809, supported by a successful public offering.
Financially, the company reported increased expenses but maintains a robust cash position for future development.
Challenges include managing expenses, regulatory transitions, and data reporting timelines, while opportunities lie in market expansion and regulatory advancements.
Overall, Viking's strategic focus on pipeline advancement and leveraging strong financials positions them for continued growth and success.

Viking Therapeutics advances breakthrough therapies with strong financial backing

Viking Therapeutics reported positive trial outcomes and a strong financial position, poised to advance breakthrough therapies for obesity and NASH.
While facing regulatory and financial challenges, Viking's innovative approach and diverse pipeline present opportunities for growth and strategic partnerships.
With a focus on advancing Phase III programs and exploring new treatment avenues, Viking remains well-positioned to drive therapeutic innovation and address unmet medical needs.

Viking Therapeutics excels in clinical trials and strategic partnerships

Viking Therapeutics delivered strong clinical progress and financial stability in Q3 2024, positioning itself for further growth and development. While facing cost challenges, the company is actively pursuing strategic opportunities to advance its pipeline and expand its market presence.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics stock fell after Novo Nordisk reported positive phase 1 results for experimental obesity drug amycretin. Amycretin achieved similar weight loss as Viking's VK2735 did in a phase 2 study.

Why Viking Therapeutics Stock Is Plunging Today

Investors are excited about the opportunity for Viking's experimental weight-loss drug VK2735. Viking doesn't compare favorably against Lilly and Novo Nordisk in most categories.

Is Viking Therapeutics Stock a Better Buy Than Eli Lilly and Novo Nordisk After the Latest Weight-Loss Drug News?

Eli Lilly

Anti-obesity medicines are currently a tremendously lucrative market. Viking Therapeutics is ascendant after publishing strong phase 2 data.

Better Weight Loss Drug Stock: Viking Therapeutics vs. Eli Lilly

SAN DIEGO , March 4, 2024 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the closing of its previously announced underwritten public offering of 7,441,650 shares of its common stock at a price to the public of $85.00 per share, which included the exercise in full by the underwriters of their option to purchase up to 970,650 additional shares of common stock.  The gross proceeds to Viking from this offering were approximately $632.5 million, before deducting underwriting discounts and commissions and offering expenses.

Viking Therapeutics Announces Closing of Public Offering of Common Stock Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Viking Therapeutics stock just rose by more than double in one day. At least one financial analyst is confident that there's more to come.

1 Wall Street Analyst Thinks Viking Therapeutics Stock Is Going to $116. Is It a Buy Around $81?

Eli Lilly's prospects look solid thanks to a key medicine, a solid lineup, and a deep pipeline. Viking Therapeutics' shares could skyrocket (again) on positive clinical developments.

Better Buy: Eli Lilly vs. Viking Therapeutics

Some Wall Street analysts said Viking's experimental obesity treatment may be "best-in-class" following the release of midstage trial data.

Viking Therapeutics emerges as a strong weight loss drug player — or takeover target

Krystal Biotech

These two mid-cap biotechs have exciting pipelines. Important breakthroughs could lead to market-beating returns.

2 Stocks That Could Turn $1,000 Into $2,500 in 5 Years

Viking Therapeutics has been one of the best-performing biotech stocks over the past three years. Not long ago, however, its shares were down by more than two-thirds from their IPO price and the company's future looked bleak.

Viking Therapeutics: A Teachable Moment About Investing for the Long Term

Investors are excited about Viking's prospects in what may become a $100 billion market. The biotech just reported positive results from a clinical trial of its weight loss drug candidate -- one aiming to compete with market leaders.

Viking Therapeutics Just Soared 120% on Optimism About Its Weight Loss Candidate. Too Late to Buy?

Shares of Viking Therapeutics recently rocketed higher in response to positive clinical trial results. Results of a mid-stage trial suggest Viking's weight management candidate can compete strongly with a similar drug from Eli Lilly.

Is Viking Therapeutics a Buy Now?

SAN DIEGO , Feb. 28, 2024 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the pricing of its  underwritten public offering of 6,471,000 shares of its common stock at a price to the public of $85.00 per share. The gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be approximately $550.0 million.

Viking Therapeutics Announces Pricing of $550 Million Public Offering of Common Stock

This week, Viking Therapeutics reported positive results from phase 2 trial of VK2735 in patients with obesity or overweight patients with a comorbidity. The company is raising $350M, but already had cash, cash equivalents and marketable securities of $362M at year-end 2023. Despite raising funds that would allow Viking Therapeutics to fund phase 3 work of VK2735 itself, the company is a potential buyout target.

Viking Therapeutics: VK2735 Data Supports A Buyout

Bitwise Bitcoin ETP Trust

iShares Russell 2000 ETF

NVIDIA

AT&T

The biggest bear argument over the past year has been the slim leadership in the market, namely concentrated in mega-cap tech stocks like the "Mag 7." However, dig deeper, and you will discover that the market is broadening quickly.

Beyond the "Mag 7": 3 Risk-On Market Forces

Viking Therapeutics' Phase II VENTURE trial of VK2735 shows statistically significant decreases in body weight, positioning it as a potential best-in-class therapy for obesity. VK2735 demonstrates promising efficacy and tolerability, potentially surpassing competitors such as semaglutide and tirzepatide. The positive outcomes from the trial support continued clinical development, with a Phase IIb trial likely as the next step.

Viking Therapeutics: Impressive Obesity Data Puts VK2735 As The Lead Asset (Rating Upgrade)

SAN DIEGO, Feb. 27, 2024 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that it has commenced an underwritten public offering of $350.0 million of shares of its common stock. Viking also intends to grant the underwriters a 30-day option to purchase up to an additional $52.5 million of shares of its common stock.

Viking Therapeutics Announces Proposed Public Offering of Common Stock

Viking Therapeutics Inc.'s stock soared 120% Tuesday to a record high, after the company announced positive results from a Phase 2 trial of its weight-loss drug VK2735, a GLP-1 receptor agonist that it's developing in both injectable and oral form as a treatment for obesity and diabetes.

Viking Therapeutics' stock more than doubles as investors cheer cheap entry to weight-loss-drug craze

CRISPR Therapeutics

Vertex Pharmaceuticals

Biotech stocks have long been a speculative, albeit rewarding way to invest in the advancement of medical technology. This industry has a wide range of companies, from start-up firms that are researching their first treatment to pharmaceutical giants that are among the largest and most powerful companies in the world.

3 Biotech Stocks Bound to Blast Off By 2029

Viking Therapeutics Inc (NASDAQ:VKTX) stock is skyrocketing today, after the biotech's experimental obesity drug helped achieve "significant" weight loss in a mid-stage study.

Biotech Stock Soars on New Weight-Loss Drug Results

Viking Therapeutics (NASDAQ: VKTX ) stock is rocketing higher on Tuesday after the clinical-stage biopharmaceutical company announced positive clinical trial results. These results come from its Phase 2 VENTURE study of VK2735.

Why Is Viking Therapeutics (VKTX) Stock Up 96% Today?

Viking Therapeutics (NASDAQ:VKTX) Inc shares skyrocketed almost 80% on Tuesday morning after the firm unveiled positive results from a trial of its VK2735 weight loss drug. Patients receiving the treatment saw “statistically significant reductions in mean body weight” after a 13-week phase 2 trial, Viking updated on Tuesday.

Viking Therapeutics soars on positive weight-loss drug results

Viking Therapeutics Inc (NASDAQ: VKTX) more than doubled on Tuesday after reporting positive results of a trial involving its weight-loss drug. Viking's GLP-1 significantly reduces weight VK2735 helped participants lose 14.7% of their body weight in thirteen weeks in a Phase 2 trial.

Viking Therapeutics stock doubles on weight-loss drug trial results

Analysts have suggested that larger pharmaceutical companies could potentially move to acquire a company like Viking Therapeutics.

Viking Therapeutics stock jumps 80% after positive weight loss drug trial results

Viking Therapeutics soared on positive phase two results for its weight-loss treatment. Eli Lilly and Novo Nordisk fell.

Viking Therapeutics Skyrockets On Weight-Loss Drug Trial Results

Patients see ‘significant' reductions in body weight during a study of a weight-loss drug developed by Viking Therapeutics, the company says.

News for Viking Therapeutics Stock (VKTX)